Last reviewed · How we verify

GrafixPL PRIME

University of Texas Southwestern Medical Center · FDA-approved active Biologic

GrafixPL PRIME is a placental tissue-derived allograft that provides a biological scaffold and growth factors to promote wound healing and tissue regeneration.

GrafixPL PRIME is a placental tissue-derived allograft that provides a biological scaffold and growth factors to promote wound healing and tissue regeneration. Used for Chronic wounds (diabetic foot ulcers, venous leg ulcers, pressure ulcers), Acute wounds and surgical wounds, Burn wounds.

At a glance

Generic nameGrafixPL PRIME
SponsorUniversity of Texas Southwestern Medical Center
Drug classBiological wound healing product / Placental tissue allograft
ModalityBiologic
Therapeutic areaWound Care / Regenerative Medicine
PhaseFDA-approved

Mechanism of action

This product is composed of dehydrated human amniotic membrane and umbilical cord tissue that contains native extracellular matrix components, growth factors, and anti-inflammatory cytokines. When applied to wounds, it provides a protective barrier, delivers bioactive molecules to the wound bed, and facilitates the body's natural healing processes through tissue regeneration rather than acting as a traditional pharmaceutical agent.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: